Literature DB >> 24602849

The influence of acute kidney injury on antimicrobial dosing in critically ill patients: are dose reductions always necessary?

Stijn Blot1, Jeffrey Lipman2, Darren M Roberts3, Jason A Roberts4.   

Abstract

Optimal dosing of antimicrobial therapy is pivotal to increase the likelihood of survival in critically ill patients with sepsis. Drug exposure that maximizes bacterial killing, minimizes the development of antimicrobial resistance, and avoids concentration-related toxicities should be considered the target of therapy. However, antimicrobial dosing is problematic as pathophysiological factors inherent to sepsis that alter may result in reduced concentrations. Alternatively, sepsis may evolve to multiple-organ dysfunction including acute kidney injury (AKI). In this case, decreased clearance of renally cleared drugs is possible, which may lead to increased concentrations that may cause drug toxicities. Consequently, when dosing antibiotics in septic patients with AKI, one should consider factors that may lead to underdosing and overdosing. Drug-specific pharmacokinetic and pharmacodynamic data may be helpful to guide dosing in these circumstances. Yet, because of the high interpatient variability in pharmacokinetics of antibiotics during sepsis, this issue remains a significant challenge.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antibiotic; ICU; Pharmacodynamics; Pharmacokinetics; Renal failure

Mesh:

Substances:

Year:  2014        PMID: 24602849     DOI: 10.1016/j.diagmicrobio.2014.01.015

Source DB:  PubMed          Journal:  Diagn Microbiol Infect Dis        ISSN: 0732-8893            Impact factor:   2.803


  24 in total

Review 1.  Understanding PK/PD.

Authors:  Jason A Roberts; Fabio Silvio Taccone; Jeffrey Lipman
Journal:  Intensive Care Med       Date:  2015-09-03       Impact factor: 17.440

Review 2.  Challenges in the management of septic shock: a narrative review.

Authors:  Daniel De Backer; Maurizio Cecconi; Jeffrey Lipman; Flavia Machado; Sheila Nainan Myatra; Marlies Ostermann; Anders Perner; Jean-Louis Teboul; Jean-Louis Vincent; Keith R Walley
Journal:  Intensive Care Med       Date:  2019-02-11       Impact factor: 17.440

3.  Intensive multidisciplinary management in critical care patients affected by severe necrotizing soft tissue infections: a cooperative method to improve the efficacy of treatment.

Authors:  Milo Gatti; Laura Elisa Gasparini; Matteo Laratta; Anna Sigurtà; Anna Rossi; Paolo Brioschi; Osvaldo Chiara; Chiara Vismara; Francesco Scaglione; Sergio Arlati
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-03-06       Impact factor: 3.267

4.  Change of teicoplanin loading dose requirement for incremental increases of systemic inflammatory response syndrome score in the setting of sepsis.

Authors:  Takafumi Nakano; Yoshihiko Nakamura; Tohru Takata; Keiichi Irie; Kazunori Sano; Osamu Imakyure; Kenichi Mishima; Koujiro Futagami
Journal:  Int J Clin Pharm       Date:  2016-04-28

5.  Pharmacokinetic assessment in patients receiving continuous RRT: perspectives from the Kidney Health Initiative.

Authors:  Thomas D Nolin; George R Aronoff; William H Fissell; Lokesh Jain; Rajnikanth Madabushi; Kellie Reynolds; Lei Zhang; Shiew Mei Huang; Rajnish Mehrotra; Michael F Flessner; John K Leypoldt; Jennifer W Witcher; Issam Zineh; Patrick Archdeacon; Prabir Roy-Chaudhury; Stuart L Goldstein
Journal:  Clin J Am Soc Nephrol       Date:  2014-09-04       Impact factor: 8.237

6.  Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment.

Authors:  Pelle Hanberg; Kristina Öbrink-Hansen; Anders Thorsted; Mats Bue; Mikkel Tøttrup; Lena E Friberg; Tore Forsingdal Hardlei; Kjeld Søballe; Jakob Gjedsted
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

7.  High target attainment for β-lactam antibiotics in intensive care unit patients when actual minimum inhibitory concentrations are applied.

Authors:  H Woksepp; A Hällgren; S Borgström; F Kullberg; A Wimmerstedt; A Oscarsson; P Nordlund; M-L Lindholm; J Bonnedahl; L Brudin; B Carlsson; T Schön
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-11-04       Impact factor: 3.267

8.  Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered?

Authors:  Maria Goul Andersen; Anders Thorsted; Merete Storgaard; Anders N Kristoffersson; Lena E Friberg; Kristina Öbrink-Hansen
Journal:  Antimicrob Agents Chemother       Date:  2018-04-26       Impact factor: 5.191

9.  Clinical Pharmacokinetics in Kidney Disease: Application to Rational Design of Dosing Regimens.

Authors:  Darren M Roberts; Jacob Sevastos; Jane E Carland; Sophie L Stocker; Tom N Lea-Henry
Journal:  Clin J Am Soc Nephrol       Date:  2018-07-24       Impact factor: 8.237

10.  Population pharmacokinetics of piperacillin in the early phase of septic shock: does standard dosing result in therapeutic plasma concentrations?

Authors:  Kristina Öbrink-Hansen; Rasmus Vestergaard Juul; Merete Storgaard; Marianne Kragh Thomsen; Tore Forsingdal Hardlei; Birgitte Brock; Mads Kreilgaard; Jakob Gjedsted
Journal:  Antimicrob Agents Chemother       Date:  2015-09-08       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.